06:15 AM EDT, 03/19/2026 (MT Newswires) -- Novo Nordisk ( NVO ) is looking to expand access to obesity treatments, like GLP-1 drugs, in Japan by targeting self-funded patients, Bloomberg News reported Thursday, citing a company executive.

"We aren't supporting any inappropriate self-funded medical treatments for cosmetic uses," Keisuke Kotani, the head of the Danish drugmaker's Japan unit, reportedly said. "We support maximizing access to patients who need the treatment."

Novo Nordisk ( NVO ) did not immediately respond to MT Newswires' request for a comment.

The company's shares were down 2% in premarket activity.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)